| The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study M Di Forti, D Quattrone, TP Freeman, G Tripoli, C Gayer-Anderson, ... The Lancet Psychiatry 6 (5), 427-436, 2019 | 761 | 2019 |
| Keep off the grass? Cannabis, cognition and addiction HV Curran, TP Freeman, C Mokrysz, DA Lewis, CJA Morgan, LH Parsons Nature Reviews Neuroscience 17 (5), 293-306, 2016 | 447 | 2016 |
| New trends in cannabis potency in USA and Europe during the last decade (2008–2017) S Chandra, MM Radwan, CG Majumdar, JC Church, TP Freeman, ... European archives of psychiatry and clinical neuroscience 269, 5-15, 2019 | 442 | 2019 |
| Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study CJA Morgan, G Schafer, TP Freeman, HV Curran The British Journal of Psychiatry 197 (4), 285-290, 2010 | 391 | 2010 |
| Examining the profile of high-potency cannabis and its association with severity of cannabis dependence TP Freeman, AR Winstock Psychological medicine 45 (15), 3181-3189, 2015 | 314 | 2015 |
| Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis CJA Morgan, TP Freeman, GL Schafer, HV Curran Neuropsychopharmacology 35 (9), 1879-1885, 2010 | 259 | 2010 |
| Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being CJA Morgan, C Gardener, G Schafer, S Swan, C Demarchi, TP Freeman, ... Psychological medicine 42 (2), 391-400, 2012 | 238 | 2012 |
| Medicinal use of cannabis based products and cannabinoids TP Freeman, C Hindocha, SF Green, MAP Bloomfield Bmj 365, 2019 | 237 | 2019 |
| The neuropsychopharmacology of cannabis: A review of human imaging studies MAP Bloomfield, C Hindocha, SF Green, MB Wall, R Lees, K Petrilli, ... Pharmacology & therapeutics 195, 132-161, 2019 | 220 | 2019 |
| Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials E Chesney, D Oliver, A Green, S Sovi, J Wilson, A Englund, TP Freeman, ... Neuropsychopharmacology 45 (11), 1799-1806, 2020 | 214 | 2020 |
| How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review AM Freeman, K Petrilli, R Lees, C Hindocha, C Mokrysz, HV Curran, ... Neuroscience & Biobehavioral Reviews 107, 696-712, 2019 | 200 | 2019 |
| Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis … C Hindocha, TP Freeman, G Schafer, C Gardener, RK Das, CJA Morgan, ... European Neuropsychopharmacology 25 (3), 325-334, 2015 | 194 | 2015 |
| Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis TP Freeman, S Craft, J Wilson, S Stylianou, M ElSohly, M Di Forti, ... Addiction 116 (5), 1000-1010, 2021 | 179 | 2021 |
| ‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration TP Freeman, V Lorenzetti Addiction 115 (7), 1207-1216, 2020 | 168 | 2020 |
| Can we make cannabis safer? A Englund, TP Freeman, RM Murray, P McGuire The Lancet Psychiatry 4 (8), 643-648, 2017 | 168 | 2017 |
| No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit C Hindocha, TP Freeman, JA Ferris, MT Lynskey, AR Winstock Frontiers in psychiatry 7, 184619, 2016 | 161 | 2016 |
| Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial TP Freeman, C Hindocha, G Baio, NDC Shaban, EM Thomas, D Astbury, ... The Lancet Psychiatry 7 (10), 865-874, 2020 | 159 | 2020 |
| Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? TP Freeman, CJA Morgan, C Hindocha, G Schafer, RK Das, HV Curran Addiction 109 (10), 1686-1694, 2014 | 153 | 2014 |
| Increasing potency and price of cannabis in Europe, 2006–16 TP Freeman, T Groshkova, A Cunningham, R Sedefov, P Griffiths, ... Addiction 114 (6), 1015-1023, 2019 | 147 | 2019 |
| Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function CJA Morgan, TP Freeman, C Hindocha, G Schafer, C Gardner, HV Curran Translational psychiatry 8 (1), 181, 2018 | 146 | 2018 |
Helen Valerie Curranprofessor of psychopharmacologyE-mailová adresa ověřena na: ucl.ac.uk
